China Resources Double-Crane Pharmaceutical Co., Ltd. Class A

China Resources Double-Crane Pharmaceutical Co., Ltd. Class A

SSSE:600062
15.32
CNY
-0.04
(-0.26%)
1.55EPS
10.69P/E
16.87BMarket Cap
Mar 19Next Earn

Total Valuation

CNY

As of September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A carries a market capitalization of 16.87B, placing it among publicly traded companies globally. Its enterprise value stands at 17.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap16.87B
Enterprise Value17.54B

Important Dates

China Resources Double-Crane Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for March 19, 2027.

Earnings Date3/19/2027

Share Statistics

As of September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A has 1.04B shares outstanding.

Shares Outstanding1.04B

Valuation Ratios

As of September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 10.69. The price-to-sales ratio is 1.55, and the price-to-book ratio stands at 1.35.

PE Ratio10.69
PS Ratio1.55
PB Ratio1.35
P/TBV Ratio1.89

Enterprise Valuation

As of September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 9.80 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.63 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.80 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 17.54B versus a market cap of 16.87B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.63
EV / EBITDA9.80
EV / EBIT9.80

Financial Position

As of September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.53, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.18, indicating elevated leverage, while an interest coverage ratio of 55.56 demonstrates strong ability to service its debt obligations.

Current Ratio2.53
Quick Ratio0.59
Debt / Equity14.18
Debt / EBITDA1.06
Interest Coverage55.56

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 817,928.18 in revenue per employee across its workforce of 13,184.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee817,928.18
Employee Count13,184.00

Taxes

CNY

Over the twelve months ended September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A recorded 212.11M in income tax expense. That works out to an effective tax rate of 11.69, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.81B, leaving 1.57B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax212.11M
Effective Tax Rate11.69

Stock Price Statistics

CNY

As of the close on November 17, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A's stock has declined approximately 20.13% over the past 52 weeks. The 50-day moving average sits at 15.98, while the 200-day moving average is 17.09.

52-Week Price Change-20.13%
50-Day Moving Average15.98
200-Day Moving Average17.09

Income Statement

CNY

Over the twelve months ended September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A generated 10.78B in revenue and converted that into 1.57B in net income, yielding earnings per share of 1.55. EBITDA reached 1.79B, while operating income came in at 1.56B.

Revenue10.78B
Gross Profit6.09B
Operating Income1.56B
Pretax Income1.81B
Net Income1.57B
EBITDA1.79B
EBIT1.79B
Earnings Per Share (EPS)1.55

Balance Sheet

CNY

As of September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A holds 2.12B in cash and equivalents against 1.90B in total debt, resulting in a net debt position of -333.68M. Total book value stands at 12.47B, with working capital of 5.46B providing operational flexibility.

Cash & Cash Equivalents2.12B
Total Debt1.90B
Net Debt-333.68M
Equity (Book Value)12.47B
Book Value Per Share12.01
Working Capital5.46B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-557.20M

Margins

Over the twelve months ended September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A posted a gross margin of 56.50, reflecting its pricing power and cost economics. The operating margin of 14.50 and net profit margin of 14.54 provide insight into operational efficiency.

Gross Margin56.50
Operating Margin14.50
Pretax Margin16.83
Profit Margin14.54
EBITDA Margin16.60

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A paid dividends of 0.56 per share. The dividend payout ratio of 35.16 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.17, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to China Resources Double-Crane Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.56
Payout Ratio35.16
Shareholder Yield0.17

Stock Splits

China Resources Double-Crane Pharmaceutical Co., Ltd. Class A's most recent stock split took place on August 16, 2018 with a 5:6 split ratio.

Last Split Date8/16/2018
Split Ratio5:6

Scores

As of September 30, 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 4.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.20